Filing Details

Accession Number:
0000950170-23-025802
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-01 19:25:51
Reporting Period:
2023-05-30
Accepted Time:
2023-06-01 19:25:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1582313 Xenon Pharmaceuticals Inc. XENE Pharmaceutical Preparations (2834) 980661854
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1620084 N. Simon Pimstone 200 - 3650 Gilmore Way
Burnaby Z4 V5G 4W8
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2023-05-30 18,006 $38.63 37,000 No 4 S Direct
Common Shares Disposition 2023-05-30 19,000 $39.90 18,000 No 4 S Direct
Common Shares Disposition 2023-05-31 12,000 $38.53 6,000 No 4 S Direct
Common Shares Acquisiton 2023-05-31 29,835 $9.85 35,835 No 4 M Direct
Common Shares Disposition 2023-05-31 6,165 $38.37 29,670 No 4 F Direct
Common Shares Disposition 2023-05-31 23,670 $38.81 6,000 No 4 S Direct
Common Shares Acquisiton 2023-05-31 50,000 $17.76 56,000 No 4 M Direct
Common Shares Disposition 2023-05-31 23,144 $38.37 32,856 No 4 F Direct
Common Shares Disposition 2023-05-31 26,856 $38.69 6,000 No 4 S Direct
Common Shares Acquisiton 2023-06-01 9,318 $7.69 15,318 No 4 M Direct
Common Shares Disposition 2023-06-01 1,860 $38.53 13,458 No 4 F Direct
Common Shares Disposition 2023-06-01 7,458 $38.97 6,000 No 4 S Direct
Common Shares Acquisiton 2023-06-01 45,000 $17.76 51,000 No 4 M Direct
Common Shares Disposition 2023-06-01 20,745 $38.53 30,255 No 4 F Direct
Common Shares Disposition 2023-06-01 24,255 $38.78 6,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2023-05-31 29,835 $0.00 29,835 $9.85
Common Shares Stock Option (Right to Buy) Disposition 2023-05-31 50,000 $0.00 50,000 $17.76
Common Shares Stock Option (Right to Buy) Disposition 2023-06-01 9,318 $0.00 9,318 $7.69
Common Shares Stock Option (Right to Buy) Disposition 2023-06-01 45,000 $0.00 45,000 $17.76
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-01-13 No 4 M Direct
45,000 2025-03-16 No 4 M Direct
30,682 2025-12-17 No 4 M Direct
0 2025-03-16 No 4 M Direct
Footnotes
  1. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.50 to $39.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  3. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.20 to $38.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  4. The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
  5. Represents the closing price of the Company's common shares on May 30, 2023 for purposes of net settlement calculations.
  6. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.66 to $39.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  7. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  8. Represents the closing price of the Company's common shares on May 31, 2023 for purposes of net settlement calculations.
  9. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.78 to $38.81, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  10. The shares subject to the options are fully vested and exercisable.